Zai Lab Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZLAB research report →
Range $35 – $35
Price Chart
About the company
Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors.
- CEO
- Ying Du
- IPO
- 2017
- Employees
- 1,784
- HQ
- Shanghai, SH, CN
Get TickerSpark's AI analysis on ZLAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.37B
- P/E
- -12.23
- Fwd P/E
- 15.78
- PEG
- -5.64
- P/S
- 6.26
- P/B
- 4.41
- EV/EBITDA
- -11.41
- Div Yield
- 0.00%
- Gross Margin
- 54.69%
- Op Margin
- -62.99%
- Net Margin
- -44.91%
- ROE
- -31.11%
- ROIC
- -31.72%
Latest fiscal year · YoY change
- Revenue
- $460.16M+15.3%
- Gross Profit
- $269.07M+7.1%
- Op Income
- $-223,572,000
- Net Income
- $-175,537,000+31.7%
- EPS
- $-1.60+38.5%
- OCF Growth
- +29.8%
- FCF Growth
- +40.6%
- 52W High
- $29.02
- 52W Low
- $15.96
- 50D MA
- $24.42
- 200D MA
- $21.42
- Beta
- 0.83
- RSI (14)
- 37
- Avg Volume
- 984.45K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Zai Lab said its third quarter showed continued China commercial stabilization while zoci advanced toward multiple late-stage milestones that could set up a U.S. filing as early as 2027.· November 5, 2026
- Total revenue was $108.2 million, and net product revenue rose 2% sequentially as the China business remained profitable.
- Management reiterated a return to year-over-year product revenue growth in 2027, supported by VYVGART SubQ, KarXT, ZEJULA, XACDURO and new NRDL access.
- Zoci remains the centerpiece: first-line SCLC data showed an 81.8% confirmed ORR and 81.9% estimated six-month PFS in 33 efficacy-evaluable patients.
- The company plans to advance zoci into a global randomized phase III study and expects three registrational studies underway by year-end, with two registrational results and a potential first U.S. BLA submission in 2027.
- ZL-1503 is approaching first-in-human data disclosure next week, and Zai also highlighted additional oncology and immunology assets entering clinical development next year.
Total revenue was $108.2 million. Net product revenue increased 2% sequentially, and the China commercial business remained profitable. R&D and SG&A expenses were described as relatively stable versus the prior-year period. Cash and cash equivalents were $659.7 million as of September 30, 2026, and the company raised approximately $250 million in equity in October at no discount to market. For zoci in first-line small cell lung cancer, management cited a confirmed objective response rate of 81.8% in 33 efficacy-evaluable patients at the selected 1.6 mg/kg dose, estimated six-month PFS of 81.9%, and grade 3 or higher zoci-related adverse events of 9.1%. For the first 15 patients with a median 10 months of follow-up, median PFS and median duration of response had not been reached. Forward-looking guidance: management expects three registrational studies underway by year-end, two registrational results in 2027, a potential first U.S. BLA submission in 2027, and a U.S. launch as early as 2028. The company also continues to expect a return to year-over-year product revenue growth in 2027.
Samantha Du framed the quarter as part of a pivotal period for the company, emphasizing that Zai Lab is moving toward a first potential U.S. BLA submission next year and that zoci could become a defining asset for the company. Her tone was confident and execution-focused, saying the company is advancing zoci aggressively, while also building beyond oncology with ZL-1503 and other global assets. She repeatedly stressed that the next two years are critical and that the company’s priorities are to deliver on clinical milestones and broaden the pipeline.
Yajing Chen said financial priorities are to restore China commercial growth, keep costs disciplined, and fund the highest-value global programs. She reported total revenue of $108.2 million, sequential net product revenue growth of 2%, stable R&D and SG&A versus the prior year, and cash of $659.7 million at September 30, 2026. She also noted the approximately $250 million equity raise in October, described China as profitable, and said the company expects year-over-year product revenue growth to return in 2027 driven by demand across priority brands and a new NRDL listing.
Analysts focused heavily on zoci’s regulatory path, asking how many patients and how much follow-up would be needed for accelerated approval in DLLEVATE. Management said the response-rate interim analysis would include 200 patients, require six months of follow-up after the first scan assessment, and use a safety database large enough to support the filing; they did not disclose the efficacy threshold. Questions also probed how zoci could compete or combine with Amgen’s Tarlatamab and whether Zai would partner or self-launch; management said the current plan is to take zoci forward itself, while remaining open to partnerships that could speed access or value creation. On epNEC, management said it has about 100 patients across single-arm datasets, discussed a bar of roughly 40% response and five to six months of durability, and said a confirmatory frontline study is planned to start early next year.
The bull case from this call is that zoci’s first-line data look unusually strong, with high response rates, encouraging durability and a tolerability profile management believes compares favorably with chemo-IO. Zai also appears to have multiple shots on goal: a planned frontline randomized study, a second-line accelerated-approval path, epNEC filing potential, and a broader pipeline including ZL-1503. On the commercial side, management sees China business stabilization already underway, profitability intact, and a clear path back to year-over-year product revenue growth in 2027.
The main risks are that nearly all of the biggest value drivers are still pre-approval and dependent on future readouts, filings, and regulatory outcomes. Management acknowledged that the field is evolving quickly, especially with Tarlatamab and possible frontline combinations, so the ultimate standard-of-care position for zoci is not yet settled. The company also still faces competitive pressure in China, including volume-based pricing dynamics, a competitive PARP landscape, and dependence on NRDL/access expansion to reaccelerate growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.9%
- Shares Outstanding
- 112.81M
- Float Shares
- 104.83M
of shares held by institutions
98 13F filers
Buy/sell ratio 0.56. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rtw Investments, LP | 10.35M | ▲ 3.78M |
| Tcg Crossover Management, LLC | 6.23M | ▲ 91.45K |
| Woodline Partners LP | 5.30M | ▲ 3.09M |
| Adar1 Capital Management, LLC | 3.38M | ▲ 12.33K |
| Ra Capital Management, L.P. | 2.82M | ▼ 2.93M |
| Goldman Sachs Group Inc | 1.91M | ▼ 402.95K |
| Frazier Life Sciences Management, L.P. | 1.90M | 0 |
| Two Sigma Investments, LP | 1.81M | ▲ 508.95K |
| Bamco Inc | 1.58M | ▼ 40.54K |
| Soleus Capital Management, L.P. | 1.54M | ▲ 1.54M |
| Citadel Advisors LLC | 1.29M | ▲ 5.21K |
| Fmr LLC | 1.07M | ▼ 1.74M |
Held by 37 ETFs
Biggest fund positions in ZLAB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | GAYNOR RICHARD | buy | 1,228 |
| Oct 1, 26 | Chen Yajing | other | 920 |
| Oct 1, 26 | Chen Yajing | other | 315 |
| Oct 1, 26 | Chen Yajing | other | 920 |
| Aug 19, 26 | Chen Yajing | sell | 260 |
| Aug 14, 26 | Chen Yajing | other | 1,250 |
| Aug 14, 26 | Chen Yajing | other | 427 |
| Aug 14, 26 | Chen Yajing | other | 1,250 |
| Aug 12, 26 | Lis William | sell | 8,506 |
| Aug 11, 26 | Chen Yajing | sell | 619 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZLAB coverage
Recent articles, reports, and earnings notes.
No research on ZLAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZLAB report →Zai Lab: The China Engine Pays The Bills, Zoci Could Pay The Upside (Initiating Buy)
seekingalpha.com · Nov 18
Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice
seekingalpha.com · Nov 16
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
businesswire.com · Nov 13
Zai Lab Announces Participation in Investor Conferences in November 2026
businesswire.com · Nov 13
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
benzinga.com · Nov 13
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
seekingalpha.com · Nov 13
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
businesswire.com · Nov 13
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
zacks.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.